June 22, 2024

News Masters

Your one-stop shop for all things trending

New Jersey Company, Tris Pharma, Leads the Charge to Address Severe Shortage of ADHD Medication

3 min read
New Jersey-based pharmaceutical company, Tris Pharma, is working to solve the severe shortage of ADHD medication in the United States by increasing production of Dyanavel XR and launching a direct-to-patient program called Dyanavel Delivered.
ADHD

New Jersey Company, Tris Pharma, Leads the Charge to Address Severe Shortage of ADHD Medication

As of November 2023, the United States is facing a severe shortage of ADHD medication. This shortage is impacting millions of Americans who rely on these medications to manage their condition. One company that is working to solve this shortage is Tris Pharma, a New Jersey-based pharmaceutical company.

Tris Pharma is the manufacturer of Dyanavel XR, an extended-release amphetamine tablet that is used to treat ADHD in children and adults. Dyanavel XR is the only generic version of amphetamine XR that is currently available in the United States.

To help address the ADHD medication shortage, Tris Pharma has increased production of Dyanavel XR. The company has also launched a direct-to-patient program called Dyanavel Delivered. This program allows patients and caregivers to seamlessly access Dyanavel XR extended-release tablets through Perigon’s digital pharmacy.

The Dyanavel Delivered program also provides patients and caregivers with enhanced medication management and support services. These services include reimbursement assistance and support to help navigate their treatment journey while reducing administrative burden for both patients and providers.

Tris Pharma’s efforts to address the ADHD medication shortage are helping to ensure that patients have access to the medications they need to manage their condition. The company’s work is also helping to reduce the stress and burden on patients and caregivers who are trying to access these medications.

How Tris Pharma’s efforts are impacting Americans

Tris Pharma’s efforts to address the ADHD medication shortage are having a positive impact on Americans who rely on these medications to manage their condition. The company’s increased production of Dyanavel XR and its direct-to-patient program are making it easier for patients and caregivers to access these medications.

The Dyanavel Delivered program is also providing patients and caregivers with enhanced medication management and support services. These services are helping patients to stay on their medication and to manage their condition more effectively.

Overall, Tris Pharma’s efforts are helping to improve the quality of life for Americans who live with ADHD. The company’s work is also helping to reduce the burden on patients, caregivers, and the healthcare system.

What Americans can do to help

There are a few things that Americans can do to help address the ADHD medication shortage. One thing is to talk to their doctor about their treatment options. If they are currently taking a medication that is in short supply, their doctor may be able to switch them to a different medication or to adjust their dosage.

Another thing that Americans can do is to be patient and understanding with their pharmacy. Pharmacists are working hard to ensure that patients have access to the medications they need. However, due to the shortage, they may not always have all medications in stock.

Finally, Americans can support Tris Pharma and other companies that are working to address the ADHD medication shortage. By purchasing Dyanavel XR and other generic ADHD medications, Americans can help to increase the supply of these medications and to make them more affordable for everyone.

Tris Pharma is a New Jersey-based pharmaceutical company that is working to solve the severe shortage of ADHD medication in the United States. The company has increased production of Dyanavel XR, the only generic version of amphetamine XR that is currently available in the United States. Tris Pharma has also launched a direct-to-patient program called Dyanavel Delivered that makes it easier for patients and caregivers to access Dyanavel XR extended-release tablets.

Tris Pharma’s efforts are having a positive impact on Americans who rely on ADHD medication to manage their condition. The company’s work is also helping to reduce the burden on patients, caregivers, and the healthcare system.

Americans can support Tris Pharma and other companies that are working to address the ADHD medication shortage by talking to their doctor about their treatment options, being patient and understanding with their pharmacy, and purchasing Dyanavel XR and other generic ADHD medications.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.